コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ld standard for the measurement of effective renal plasma flow.
2 ld standard for the measurement of effective renal plasma flow.
3 ld standard for the measurement of effective renal plasma flow.
4 lomerular hyperfiltration and an increase in renal plasma flow.
5 61) without significant changes to effective renal plasma flow.
6 AH), is used clinically to measure effective renal plasma flow.
7 d that has historically been used to measure renal plasma flow.
9 anied by declines in plasma NO and effective renal plasma flow and an increase in renal vascular resi
10 ng patients with SCD have elevated effective renal plasma flow and glomerular filtration rates, which
13 h chronic heart failure, serelaxin increased renal plasma flow and reduced the increase in filtration
15 ession, greater body mass index, lower basal renal plasma flow, and higher diastolic blood pressure t
16 s associated with lower GFR, lower effective renal plasma flow, and higher filtration fraction, even
18 rate; GFR) and paraaminohippurate (effective renal plasma flow) clearances were measured in individua
19 lin (GFR) and para-aminohippurate (effective renal plasma flow) clearances, tubular sodium handling,
20 tracer with a capacity to measure effective renal plasma flow comparable to that of the clinical gol
22 still substantial and sustained increases in renal plasma flow, cortical blood flow (20 +/- 4% increa
24 partmental analysis for estimating effective renal plasma flow (ERPF in units of milliliters per minu
25 nstrumented rats increases GFR and effective renal plasma flow (ERPF) and decreases effective renal v
26 r recombinant human RLX 2 (rhRLX), effective renal plasma flow (ERPF) and glomerular filtration rate
27 ronic inhibition of NO synthase on effective renal plasma flow (ERPF) and glomerular filtration rate
28 n 3 d) that includes estimation of effective renal plasma flow (ERPF) from a single plasma sample in
29 dy, we retrospectively review 1626 effective renal plasma flow (ERPF) measurements in 197 patients wi
31 n cortical blood flow (34 +/- 12% increase), renal plasma flow, GFR, and sodium excretion; however, t
32 iltration rate (I-iothalamate) and effective renal plasma flow (I-hippuran) measured 4 months before
35 ficant changes in mean arterial pressure and renal plasma flow in either C or D rats but reduced glom
36 renin inhibition led to a larger increase in renal plasma flow in healthy human volunteers studied on
37 perfiltrating and showed the largest rise in renal plasma flow in response to irbesartan, whereas ren
41 llagen I in UUO-treated kidneys and enhanced renal plasma flow measured by Technetium-99m mercaptoace
42 on GFR (measured by iothalamate clearance), renal plasma flow (measured by para-amino hippurate clea
44 creased plasma renin activity (P < 0.01) and renal plasma flow (P < 0.01); the latter effect plateaue
48 difference between serelaxin and placebo on renal plasma flow (para-aminohippuric acid clearance) an
49 hanges from baseline mean arterial pressure, renal plasma flow, plasma renin activity, aldosterone, u
51 ced the glomerular filtration rate (GFR) and renal plasma flow rate in diabetic rats, despite variabl
54 asma flow in response to irbesartan, whereas renal plasma flow rose less and GFR fell in patients wit
55 mide on glomerular filtration rate (GFR) and renal plasma flow (RPF) in heart failure patients are co
56 intrarenal renin activity, we have examined renal plasma flow (RPF) responses in a standardized prot
59 easured glomerular filtration rate (GFR) and renal plasma flow (RPF), and analysed renal structural i
61 ong the three centers, but systolic BP, GFR, renal plasma flow (RPF), and filtration fraction were lo
64 mable from glomerular filtration rate (GFR), renal plasma flow (RPF), blood pressure, hematocrit, and
65 s (T1D) and relate the ratio to albuminuria, renal plasma flow (RPF), fat mass, and insulin sensitivi
66 s showed parallel increases in single-kidney renal plasma flow (RPF), renocortical volume, and glomer
68 There were no differences in GFR, effective renal plasma flow, urine output, or sodium excretion for
69 y [GC]/mass spectrometry [MS] analysis), and renal plasma flow was determined with paraaminohippurate
72 sured with infusion of [6-(2)H2]glucose, and renal plasma flow was measured by para-aminohippurate cl